Geron Corp. (GERN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

BOSTON, Sept. 27, 2018 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Geron Corporation. ("Geron" or the "Company") (NASDAQ: GERN) and certain of its officers and directors violated federal securities laws.

On September 27, 2018, Geron announced that "Janssen Biotech, Inc. (Janssen) has terminated the 2014 Collaboration and License Agreement (CLA) with the Company. Janssen stated in their press release issued today that they made this decision as the result of a strategic portfolio evaluation and prioritization of assets within their portfolio. As such, Geron has regained the global rights to develop and commercialize imetelstat, a first-in-class telomerase inhibitor."

On this news, Geron stock has plunged more than 65%.

If you purchased or otherwise acquired GERN securities and have questions about your legal rights, or possess information relevant to this investigation, you are encouraged to contact attorney John DeFelice at (888) 868-2385, by email at [email protected], attorney Jacob Walker at [email protected] or by visiting http://shareholder.law/geron.

Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP
John DeFelice
(617) 398-5600 phone
155 Federal Street, Suite 400
Boston, MA 02110
[email protected]

SOURCE Block & Leviton LLP

Related Links

http://www.blockesq.com